Comparing Tisa-Cel to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL
As a second-line treatment for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL), the autologous CD19-targeting chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) led to...
Adding Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Treatment with polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) led to a 27% reduction in the relative risk of disease...
ctDNA: A Noninvasive Tool for Diagnosis and Outcome Prediction in CNS Lymphomas
Circulating tumor DNA (ctDNA) accurately reflects tumor burden and may serve as a useful clinical biomarker for risk, outcome, and surgery-free lymphoma classification in...
Comparing AHCT Versus CAR T-Cell Therapy in Relapsed DLBCL
Compared with chimeric antigen receptor (CAR) T-cell therapy, autologous hematopoietic cell transplantation (AHCT) led to a lower incidence of relapse and superior overall survival...
Reader Responses: What are the treatment options for this patient with aggressive blastoid mantle cell lymphoma and high bilirubin?
Here’s how readers responded to a You Make the Call question about treatment options for a patient with aggressive blastoid mantle cell lymphoma and...
You Make the Call: What are the treatment options for this patient with aggressive blastoid mantle cell lymphoma and high bilirubin?
This month, Alexey V. Danilov, MD, PhD, discusses treatment options for a patient with aggressive blastoid mantle cell lymphoma and high bilirubin. And don't forget to...
